{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:08:15Z","timestamp":1787987295873,"version":"build-2784847793"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejim.2015.12.017","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T12:21:40Z","timestamp":1453983700000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Adverse drug reactions and organ damage: The liver"],"prefix":"10.1016","volume":"28","author":[{"given":"Anna","family":"Licata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2015.12.017_bb0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00204-015-1456-2","article-title":"Bjornssn. Drug-induced liver injury: an overview over the most critical compounds","volume":"89","author":"Einar","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0010","doi-asserted-by":"crossref","unstructured":"Lee W. Acetaminophen-related acute liver failure in the United States. Hepatol Res;38 (S1):S3-8.","DOI":"10.1111\/j.1872-034X.2008.00419.x"},{"key":"10.1016\/j.ejim.2015.12.017_bb0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.ejim.2015.12.017_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin\u2013clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","author":"Lucena","year":"2006","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2015.12.017_bb0025","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.ejim.2015.12.017_bb0030","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0035","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ejim.2015.12.017_bb0040","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0045","doi-asserted-by":"crossref","unstructured":"Andrade RJ, Lucena MI, Fern\u00e1ndez MC, Pelaez G, Pachkoria K, Garc\u00eda-Ruiz E et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129(2):512\u201321.","DOI":"10.1016\/j.gastro.2005.05.006"},{"key":"10.1016\/j.ejim.2015.12.017_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00228-010-0981-4","article-title":"Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health","volume":"67","author":"Vitalone","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejim.2015.12.017_bb0055","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.27317","article-title":"Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network","volume":"60","author":"Navarro","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11739-012-0777-x","article-title":"Herbal hepatotoxicity: a hidden epidemic","volume":"8","author":"A Licata","year":"2013","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ejim.2015.12.017_bb0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejim.2015.12.017_bb0075","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2796.2007.01818.x","article-title":"Acute liver failure in Sweden: etiology and outcome","volume":"262","author":"Wei","year":"2007","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejim.2015.12.017_bb0085","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hep.20445","article-title":"Drug-Induced Liver Injury Network (DILIN)","volume":"40","author":"Hoofnagle","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejim.2015.12.017_bb0090","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.ejim.2015.12.017_bb0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1053\/j.gastro.2013.12.032","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspective","volume":"146","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0105","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42(2):481\u20139","DOI":"10.1002\/hep.20800"},{"key":"10.1016\/j.ejim.2015.12.017_bb0110","doi-asserted-by":"crossref","unstructured":"Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J. Hepatol. 2015 ;63(2):503\u201314","DOI":"10.1016\/j.jhep.2015.04.016"},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOG.0b013e3283383c7c","article-title":"Drug-induced liver injury: a clinical update","volume":"26","author":"Ghabril","year":"2010","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-010-0977-0","article-title":"Polypharmacy, length of hospital stay, and in\u2013hospital mortality among elderly patients in internal medicine wards. The Reposi study","volume":"5","author":"Nobili","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s11739-014-1124-1","article-title":"NobiliA: Reposi investigators","volume":"9","author":"Mannucci","year":"2014","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.ejim.2015.12.017_bb0130","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2015.12.017_bb0140","series-title":"Philadelphia: Lippincott Williams & Wilkins","article-title":"Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1999"},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3748\/wjg.v13.i3.329","article-title":"Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists","volume":"13","author":"Andrade","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(98)80188-8","article-title":"Nimesulide-induced acute hepatitis: evidence from six cases","volume":"29","author":"Van Steenbergen","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs \u2014 I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0160","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs \u2014 II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0165","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis","volume":"26","author":"Maria","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","article-title":"Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity","volume":"33","author":"Lucena","year":"2001","journal-title":"Hepatology"},{"issue":"S6","key":"10.1016\/j.ejim.2015.12.017_bb0175","first-page":"S227","article-title":"Drug-induced liver inujry: the impact of non steroidal anti-inflammatory drugs (NSAIDS)","volume":"58","author":"Licata","year":"2013","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ejim.2015.12.017_bb0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dld.2009.06.009","article-title":"Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication","volume":"42","author":"Licata","year":"2010","journal-title":"Dig. Liver Dis."},{"issue":"S1","key":"10.1016\/j.ejim.2015.12.017_bb0185","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/S0168-8278(11)60499-6","article-title":"Pattern of drug induced liver injury: the impact of amoxicillin\u2013clavulanate on severity of clinical course","volume":"54","author":"Licata","year":"2011","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0190","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00228-011-1201-6","article-title":"Fluoroquinolone-induced liver injury: three new cases and a review of the literature","volume":"68","author":"Licata","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejim.2015.12.017_bb0195","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.dld.2014.08.040","article-title":"Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study","volume":"46","author":"Licata","year":"2014","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0200","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1553-2712.2008.00296.x","article-title":"Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose","volume":"16","author":"Doyon","year":"2009","journal-title":"Acad. Emerg. Med."},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2036.2009.04175.x","article-title":"Review article: the current management of acute liver failure","volume":"31","author":"Craig","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.ejim.2015.12.017_bb0210","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650903438566","article-title":"Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report","volume":"47","author":"Bronstein","year":"2009","journal-title":"Clin. Toxicol. (Phila.)"},{"issue":"6","key":"10.1016\/j.ejim.2015.12.017_bb0215","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.ejim.2015.12.017_bb0220","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.amepre.2011.02.026","article-title":"Emergency department visits for overdoses of acetaminophen containing products","volume":"40","author":"Budnitz","year":"2011","journal-title":"Am. J. Prev. Med."},{"issue":"33","key":"10.1016\/j.ejim.2015.12.017_bb0225","doi-asserted-by":"crossref","first-page":"12169","DOI":"10.1073\/pnas.1412608111","article-title":"Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis","volume":"111","author":"Ward","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.ejim.2015.12.017_bb0230","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1073\/pnas.0813371106","article-title":"Circulating microRNAs, potential biomarkers for drug-induced liver injury","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0235","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.24538","article-title":"Circulating microRNAs as potential markers of human drug-induced liver injury","volume":"54","author":"Starkey Lewis","year":"2011","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.ejim.2015.12.017_bb0240","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3109\/15563650.2013.830733","article-title":"Predicting the requirement for N-acetylcysteine in paracetamol poisoning from reported dose","volume":"51","author":"Duffull","year":"2013","journal-title":"Clin. Toxicol."},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0245","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5694\/j.1326-5377.2008.tb01625.x","volume":"188","author":"Daly","year":"2008","journal-title":"Med. J. Aust."},{"issue":"1-2","key":"10.1016\/j.ejim.2015.12.017_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1515\/bc.2011.006","article-title":"Evolution of ABC transporters by gene duplication and their role in human disease","volume":"392","author":"Moitra","year":"2011","journal-title":"Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-9556(25)07393-3","article-title":"Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation","volume":"21","author":"Yun","year":"1993","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.ejim.2015.12.017_bb0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.84.2.551","article-title":"Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug","volume":"84","author":"Beaune","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"339","key":"10.1016\/j.ejim.2015.12.017_bb0265","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"22","author":"Trauner","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejim.2015.12.017_bb0270","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","article-title":"Schwabe RFCell death and cell death responses in liver disease: mechanisms and clinical relevance","volume":"147","author":"Luedde","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0275","doi-asserted-by":"crossref","unstructured":"Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim. Biophys. Acta 2006;1757(9-10):1371\u201387","DOI":"10.1016\/j.bbabio.2006.06.014"},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ejim.2015.12.017_bb0285","doi-asserted-by":"crossref","first-page":"e81974","DOI":"10.1371\/journal.pone.0081974","article-title":"Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance","volume":"8","author":"Steuerwald","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ejim.2015.12.017_bb0290","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.cgh.2007.08.007","article-title":"Serum apoptosis markers in acute liver failure: a pilot study","volume":"5","author":"Rutherford","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0295","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2012.07.011","article-title":"Pathogenesis of liver injury in acute liver failure","volume":"143","author":"Chung","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0300","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2036.2011.04982.x","article-title":"Serum proteomic profiling in patients with drug-induced liver injury","volume":"35","author":"Bell","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejim.2015.12.017_bb0305","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2217\/pgs.09.111","article-title":"Drug-induced liver injury: insights from genetic studies","volume":"10","author":"Andrade","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0310","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/pgs.10.24","article-title":"Drug-induced liver injury: past, present and future","volume":"11","author":"Daly","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry. The dilemma of the relationship to autoimmune hepatitis","author":"Lucena","year":"2011","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.ejim.2015.12.017_bb0320","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejim.2015.12.017_bb0325","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/pgs.09.37","article-title":"Pharmacogenomics of adverse drug reactions: practical applications and perspectives","volume":"10","author":"Becquemont","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0330","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls","volume":"447","author":"Wellcome Trust Case Control Consortium","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2015.12.017_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-pharmtox-010611-134743","article-title":"Using genome-wide association studies to identify genes important in serious adverse drug reactions","volume":"52","author":"Daly","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.ejim.2015.12.017_bb0340","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/FPC.0b013e3283589a76","article-title":"Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs","volume":"22","author":"Urban","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0345","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/14622416.7.4.633","article-title":"EUDRAGENE: European collaboration to establish a case\u2013control DNA collection for studying the genetic basis of adverse drug reactions","volume":"7","author":"Molokhia","year":"2006","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.ejim.2015.12.017_bb0350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1399-6576.1985.tb02242.x","article-title":"HLA antigens in patients with unexplained hepatitis followinghalothaneanesthesia","volume":"29","author":"Otsuka","year":"1985","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.ejim.2015.12.017_bb0355","doi-asserted-by":"crossref","unstructured":"Berson A, Freneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of HLA in hepatotoxicity \u2014 an exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol.1994, 20:336\u2013342.","DOI":"10.1016\/S0168-8278(94)80004-9"},{"key":"10.1016\/j.ejim.2015.12.017_bb0360","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.47.5.717","article-title":"MillsPR: co-amoxiclav jaundice: clinical and histological features and HLA classII association","volume":"47","author":"O'Donohue","year":"2000","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0365","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin\u2013clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ejim.2015.12.017_bb0370","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.26077","article-title":"HLA B*57:01 restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury","volume":"57","author":"Monshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0375","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejim.2015.12.017_bb0380","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejim.2015.12.017_bb0385","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2015.12.017_bb0390","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0395","first-page":"2","article-title":"Pharmacogenomics of adverse events","volume":"5","author":"Daly","year":"2013","journal-title":"Gend. Med."},{"key":"10.1016\/j.ejim.2015.12.017_bb0400","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.20205","article-title":"Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity","volume":"39","author":"Aithal","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12094-012-0936-6","article-title":"Specific genetic polymorphisms of IL10\u2013592 AA and IL10\u2013819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients","volume":"15","author":"Liang","year":"2013","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2008.03.017","article-title":"Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome","volume":"49","author":"Pachkoria","year":"2008","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ejim.2015.12.017_bb0415","doi-asserted-by":"crossref","first-page":"e0118862","DOI":"10.1371\/journal.pone.0118862","article-title":"Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case\u2013control study","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ejim.2015.12.017_bb0420","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejim.2015.12.017_bb0425","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2006-04-014779","article-title":"Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6gGal1","volume":"108","author":"Nasirikerani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejim.2015.12.017_bb0430","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11882-008-0077-8","article-title":"STAT4: genetics, mechanisms, and implications for autoimmunity","volume":"8","author":"Korman","year":"2008","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.ejim.2015.12.017_bb0435","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/clpt.2010.355","article-title":"A fresh look at the mechanism of isoniazid-induced hepatotoxicity","volume":"89","author":"Metushi","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejim.2015.12.017_bb0440","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/03602532.2011.605790","article-title":"Genetic association studies in drug-induced liver injury","volume":"44","author":"Daly","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejim.2015.12.017_bb0445","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbamcr.2006.04.014","article-title":"Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration","volume":"1773","author":"Geier","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejim.2015.12.017_bb0450","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2005.05.020","article-title":"Impaired expression and function of the bile saltexport pump due to three novel ABCB11 mutations in intrahepaticcholestasis","volume":"43","author":"Noe","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug induced liver injury","volume":"17","author":"Lang","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0460","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2015.12.017_bb0465","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.fpc.0000236337.41799.b3","article-title":"MRP2 haplotypes confer differential susceptibility to toxic liver injury","volume":"17","author":"Choi","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.ejim.2015.12.017_bb0470","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","article-title":"Toxic and drug-induced myopathies","volume":"80","author":"Dalakas","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejim.2015.12.017_bb0475","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2014 a genome wide study","volume":"359","author":"Link","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2015.12.017_bb0480","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejim.2015.12.017_bb0485","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T07:38:15Z","timestamp":1748763495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":97,"alternative-id":["S0953620515004458"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.12.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions and organ damage: The liver","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}